Biotech | August 02, 2021
Bharat Biotech gets WHO prequalification for ROTAVAC 5D
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The first batch will be shipped to the Gamaleya Center for the quality control
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
Subscribe To Our Newsletter & Stay Updated
